## Evaluate the anti-proliferative activity of 2-oxo-pyridine and 1'*H*-spiro-pyridine derivatives as a new class of EGFR<sup>Wt</sup> and VEGFR-2 inhibitors with apoptotic inducers

Reham R. Raslan<sup>1</sup>, Yousry A. Ammar<sup>2,\*</sup>, Sawsan A. Fouad<sup>1</sup>, Sadia A. Hessein<sup>1</sup>, Nadia A. M. Shmiess<sup>1</sup>, and Ahmed Ragab<sup>2,\*</sup>

<sup>1</sup>Department of Chemistry, Faculty of Science (Girls), Al-Azhar University, Nasr City, Cairo, Egypt. <sup>2</sup>Department of Chemistry, Faculty of Science (Boys), Al-Azhar University, Nasr City, 11884, Cairo, Egypt.



a :













































![](_page_24_Figure_0.jpeg)

![](_page_26_Figure_0.jpeg)

![](_page_27_Figure_0.jpeg)

![](_page_28_Figure_0.jpeg)

![](_page_29_Figure_0.jpeg)

![](_page_30_Figure_0.jpeg)

![](_page_31_Figure_0.jpeg)

![](_page_32_Figure_0.jpeg)

![](_page_33_Figure_0.jpeg)

#### **Biological evaluation raw materials**

### Average of Relative viability of cells (%)

Conc.(µM)	HePG-2	Caco-2
	DOX	
100	6.3	15.1
50	11.2	24.7
25	14.1	36.8
12.5	28.3	42.6
6.25	45.8	62.0
3.125	57.6	78.3
1.56	71.2	100
	2	
100	36.4	34.6
50	51.2	45.1
25	64.7	57.9
12.5	76.1	70.2
6.25	90.3	91.4
3.125	100	100
1.56	100	100
	<b>3</b> a	
100	47.4	49.4
50	58.1	60.2
25	72.6	73.8
12.5	83.5	89.5
6.25	96.0	100
3.125	100	100
1.56	100	100
	<b>3</b> b	
100	40.7	47.8
50	53.1	55.2
25	72.0	73.6
12.5	90.3	85.4
6.25	100	97.7
3.125	100	100
1.56	100	100
	4	
100	26.5	33.9
50	37.9	44.0
25	50.0	52.1
12.5	64.2	70.6
6.25	78.6	85.2

3.125	96.5	100
1.56	100	100
	5	
100	13.0	8.3
50	18.6	16.9
25	29.7	26.7
12.5	38.1	40.1
6.25	64.5	59.2
3.125	77.2	79.6
1.56	98.5	95.3
	6	
100	35.6	34.6
50	42.7	48.3
25	56.3	60.7
12.5	68.1	73.9
6.25	90.2	87.5
3.125	100	100
1.56	100	100
100	7	100
100	10.7	96
50	10.7	16.1
25	23.5	24.0
<u> </u>	25.5	24.9
6 25	61.3	50.4
3 125	60.3	72 7
1 56	9/1 2	96.0
1.00	8	20.0
100	78	18 3
50	16.1	27.1
25	26.3	33.4
12.5	33.9	40.6
6.25	58.6	69.2
3.125	74.5	85.9
1.56	88.2	100
	9	
100	30.2	38.9
50	42.7	53.1
25	56.1	64.8
12.5	67.5	77.6
6.25	79.4	98.5
3.125	99.8	100
1.56	100	100
	10	
100	24 5	293
50	35.1	44.7
<b>U</b> U		/

25	50.9	59.1
12.5	63.6	64.0
6.25	71.8	95.4
3.125	90.2	100
1.56	100	100
	11	
100	18.3	23.7
50	25.6	30.2
25	33.1	39.1
12.5	50.4	55.3
6.25	67.9	73.8
3.125	88.0	90.4
1.56	100	100
100	21.3	26.1
50	32.8	38.3

## Lab Report

Ser	Sam	ple		RT- Res Fold C		
	code	cells	IC50	Вах	Bcl2	
1	5	Caco2	9.78	4.508	0.436	
2	7	Caco2	7.83	7.508	0.194	
3	8	Caco2	13.61	4.188	0.275	
4	Staurosporine	Caco2	5.07	7.648	0.321	
5	control	Caco2		1	1	

![](_page_38_Picture_1.jpeg)

14 Hilly Street Mortlake NSW 2137 Australia
T + 61 2 9736 1320
F + 61 2 9736 1364
W www.corbettlifescience.com

## **Quantitation Report**

**Experiment Information** 

Run 2022-08-12 (1)
2022-08-12 01:55:02 PM
2022-08-12 04:27:17 PM
ERA
Rotor-Gene 1.7.87
The Run Signature is valid.
10.
9.33

Quantitation data

This report generated by Rotor-Gene 6000 Series Software 1.7 (Build 87) Copyright ©2000-2006 Corbett Research, a Division of Corbett Life Science. All rights reserved. ISO 9001:2000 (Reg. No. QEC21313)

14		
ysterr		primers
₹ V	Bax	: F 5'- TCAGGATGCGTCCACCAAGAAG-3',
	Bax	: R 5'-TGTGTCCACGGCGGCAATCATC -3'.
✓		
Quality Endorsed	bcl2	: F 5'-ATGTGTGTGGAGACCGTCAA -3',
Company ISO SM1 UK 21313	bcl2	: R 5'-GCCGTACAGTTCCACAAAGG -3'.
SAI Globel		

GAPDH : F 5'- GTCTCCTCTGACTTCAACAGCG-3'

GAPDH : R 5'- ACCACCCTGTTGCTGTAGCCAA-3'

	Sample		Вах								
			Co	ontrol cell	s		FLD				
Ser	code	Conc	GAPDH	Вах	ΔCTC	GAPDH	Вах	ΔCTE	ΔΔ CT	2^ ΔΔCT	
			HC	TC	TC- HC	HE	TE	TE-HE	ΔCTΕ- ΔCTC	E=1.849	
1	5		22.07	35.25	13.18	22.18	32.91	10.73	-2.45	4.508	
2	7	-	22.07	35.25	13.18	22.29	32.19	9.9	-3.28	7.508	
3	8		22.07	35.25	13.18	21.94	32.79	10.85	-2.33	4.188	
4	Staurosporine	-	22.07	35.25	13.18	22.36	32.23	9.87	-3.31	7.648	
5	control		22.07	35.25	13.18	22.07	35.25	13.18	0	1	

	Sample	bcl2									
			Co	ontrol cell	S		Test cells				
Ser	code	Conc	GAPDH	bcl2	ΔCTC	GAPDH	bcl2	ΔCTE	ΔΔ CT	2^ ΔΔCT	
			HC	тс	TC- HC	HE	TE	TE-HE	ΔCTE- ΔCTC	E=1.849	
1	5		22.07	27.49	5.42	22.18	28.95	6.77	1.35	0.436	
2	7		22.07	27.49	5.42	21.94	30.03	8.09	2.67	0.194	
3	8	-	22.07	27.49	5.42	22.29	29.81	7.52	2.1	0.275	
4	Staurosporine		22.07	27.49	5.42	22.36	29.63	7.27	1.85	0.321	
5	control		22.07	27.49	5.42	22.07	27.49	5.42	0	1	

## Lab Report

	Compound	EGFR			
ser	code	MW	IC50		
		g/mol	uM	SD ±	
1	7	293	0.124	0.009	
***	Erlotenib	393.436	0.033	0.002	

#### Detailed Results

EGFR												
code	IC50	conc	log	%inh	T2	T1	ΔT	RFU2	RFU1	ΔRFU	slope	K.Activity
7		100	2	93.03	30	0	30	6.97	0	6.97	3.3333	8.36408
<u>ب</u>												
·		10	1	88.41	30	0	30	11.59	0	11.59	3.3333	13.9081
<b>2</b>	-	1	0	68.08	30	0	30	31.92	0	31.92	3.3333	38.3044
		0.1	-1	50.14	30	0	30	49.86	0	49.86	3.3333	59.8326
		0.01	-2	27.33	30	0	30	72.67	0	72.67	3.3333	87.2049
EC				0	30	0	30	100	0	100	3.3333	120
code	IC50	conc	log	%inh	T2	T1	ΔT	RFU2	RFU1	ΔRFU	slope	K.Activity
Erlotenib		100	2	95.73	30	0	30	4.27	0	4.27	3.3333	5.12405
,un		10	1	92.85	30	0	30	7.15	0	7.15	3.3333	8.58009
		1	0	80.06	30	0	30	19.94	0	19.94	3.3333	23.9282
		0.1	-1	57.63	30	0	30	42.37	0	42.37	3.3333	50.8445
		0.01	-2	36.88	30	0	30	63.12	0	63.12	3.3333	75.7448
EC				0	30	0	30	100	0	100	3.3333	120
									l			
	s	2		y =	16.90	67x+	65.3	98		E	rlotenil	9
					<u> </u>	3 min		μ				
		-3 -2	-1		1		<u>ا</u> لا				•	
											2	-1

se	r	Compound		VEGFR2	
		code	MW	IC50	SD
			g/mol	uM	±
1		7	293	0.221	0.009
**:	*	Sorafenib	464.8	0.043	0.002

**Detailed results** 

VEGFR2

code	IC50	conc	log	%inh	T2	T1	ΔT	RFU2	RFU1	ΔRFU	slope	K.Activity
7		100	2	92.44	30	0	30	7.56	0	7.56	3.3333	9.07209
~												
		10	1	87.03	30	0	30	12.97	0	12.97	3.3333	15.5642
		1	0	64.12	30	0	30	35.88	0	35.88	3.3333	43.0564
		0.1	-1	44.03	30	0	30	55.97	0	55.97	3.3333	67.1647
		0.01	-2	22.41	30	0	30	77.59	0	77.59	3.3333	93.1089
EC				0	30	0	30	100	0	100	3.3333	120
code	IC50	conc	log	%inh	T2	T1	ΔT	RFU2	RFU1	ΔRFU	slope	K.Activity
Sorafenib		100	2	95.93	30	0	30	4.07	0	4.07	3.3333	4.88405
	_											
·		10	1	92.08	30	0	30	7.92	0	7.92	3.3333	9.5041
		1	0	80.89	30	0	30	19.11	0	19.11	3.3333	22.9322
		0.1	-1	53.47	30	0	30	46.53	0	46.53	3.3333	55.8366
		0.01	-2	35.81	30	0	30	64.19	0	64.19	3.3333	77.0288
EC				0	30	0	30	100	0	100	3.3333	120

![](_page_41_Figure_4.jpeg)

![](_page_41_Figure_5.jpeg)

# Docking simulation figures

![](_page_43_Figure_0.jpeg)

2D binding mode of co-crystallized ligand inside Bcl-2 binding pocket (**PDB**: 4AQ3)

![](_page_44_Figure_0.jpeg)

3D binding mode of co-crystallized ligand inside Bcl-2 binding pocket (**PDB**: 4AQ3)

![](_page_45_Figure_0.jpeg)

2D binding mode of 2-oxo-1'*H*-spiro-indoline-3,4'-pyridine 7 inside Bcl-2 binding pocket (**PDB**: 4AQ3)

![](_page_46_Figure_0.jpeg)

3D binding mode of 2-oxo-1'H-spiro-indoline-3,4'-pyridine 7 inside Bcl-2 binding pocket (PDB: 4AQ3)

![](_page_47_Figure_0.jpeg)

2D binding mode of co-crystallized ligand inside the EGFR binding pocket (PDB: 1M17)

![](_page_48_Picture_0.jpeg)

3D binding mode of co-crystallized ligand inside the EGFR binding pocket (PDB: 1M17)

Glu 738

![](_page_49_Figure_1.jpeg)

2D binding mode of 2-oxo-1'*H*-spiro-indoline-3,4'-pyridine **7** inside the EGFR binding pocket (**PDB**: 1M17)

![](_page_50_Figure_0.jpeg)

3D binding mode of 2-oxo-1'*H*-spiro-indoline-3,4'-pyridine 7 inside the EGFR binding pocket (**PDB**: 1M17)

![](_page_51_Figure_0.jpeg)

2D binding mode of co-crystallized ligand inside the VEGFR-2 binding pocket (PDB: 4ASD)

![](_page_52_Figure_0.jpeg)

3D binding mode of co-crystallized ligand inside the VEGFR-2 binding pocket (PDB: 4ASD)

![](_page_53_Figure_0.jpeg)

2D binding mode of 2-oxo-1'H-spiro-indoline-3,4'-pyridine 7 inside the VEGFR-2 binding pocket (PDB: 4ASD)

![](_page_54_Picture_0.jpeg)

3D binding mode of 2-oxo-1'H-spiro-indoline-3,4'-pyridine 7 inside the VEGFR-2 binding pocket (PDB: 4ASD)